BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で163.97%の成長率を示しています。
黒字転換
同社は黒字転換を果たし、最新の年間純利益はUSD です。
割高
同社の最新のPEは-5.21で、過去3年間の水準と比較して高値圏にあります。
機関投資家の買い増し
最新の機関投資家の保有株数は235.68M株で、前四半期比で2.71%増加しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は0.05です。